Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMSB068)

• Drug Name: PF-04449913 Drug Info
• Synonyms: Glasdegib; 1095173-27-5; PF 04449913; UNII-K673DMO5H9; K673DMO5H9; CHEMBL2043437; Glasdegib (PF-04449913); Glasdegib [USAN:INN]; Glasdegib (USAN/INN); PF-04449913;Glasdegib; GTPL8201; Glasdegib(PF-04449913); EX-A858; MolPort-035-789-706; SFNSLLSYNZWZQG-VQIMIIECSA-N; ZINC68251434; PF-913; BDBM50385635; 2640AH; AKOS027324121; CS-2

Indication

Disease Entry	ICD 11	Status	REF
Chronic myelomonocytic leukaemia	2A40	Approved	[1]
Solid tumour/cancer	2A00-2F9Z	Approved	[2]

• Cross-matching ID:
  PubChem CID: 25166913
  ChEBI ID: CHEBI:145428
  CAS Number: CAS 1095173-27-5
  TTD Drug ID: DMSB068
  INTEDE Drug ID: DR0774
  ACDINA Drug ID: D01126

Molecule-Related Drug Atlas

Drug(s) Targeting Smoothened homolog (SMO)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Vismodegib	DM5IXKQ	Basal cell carcinoma	2C32	Approved	[6]
LDE225	DMM9F25	Basal cell carcinoma	2C32	Phase 2	[7]
LY2940680	DMTJWIQ	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[4]
BMS-833923	DM459Q7	Solid tumour/cancer	2A00-2F9Z	Phase 1b	[8]
LEQ-506	DM5INZP	Solid tumour/cancer	2A00-2F9Z	Phase 1	[9]
TAK-441	DM7DFBL	Solid tumour/cancer	2A00-2F9Z	Phase 1	[10]
PMID25726713-Compound-49	DM2CT4G	N. A.	N. A.	Patented	[11]
PMID25726713-Compound-51	DMF0OW4	N. A.	N. A.	Patented	[11]
PMID25726713-Compound-48	DMSIOUA	N. A.	N. A.	Patented	[11]
PMID25726713-Compound-47	DMXE5KM	N. A.	N. A.	Patented	[11]

Drug(s) Targeting Hedgehog signaling pathway (HS pathway)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Itraconazole	DMCR1MV	Aspergillosis	1F20	Approved	[2]
Patidegib	DM2NJYC	Basal cell carcinoma	2C32	Phase 2	[12]
ENV-101	DMFOI3T	Idiopathic pulmonary fibrosis	CB03.4	Phase 2	[13]

Drug(s) Targeting Serine/threonine-protein kinase mTOR (mTOR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sirolimus	DMGW1ID	Advanced cancer	2A00-2F9Z	Approved	[14]
Temsirolimus	DMS104F	Renal cell carcinoma	2C90	Approved	[15]
Everolimus	DM8X2EH	Advanced cancer	2A00-2F9Z	Approved	[16]
Novolimus	DM6ZPLQ	Artery stenosis	BD52	Approved	[17]
Zotarolimus	DMRMCXW	Solid tumour/cancer	2A00-2F9Z	Approved	[18]
Ridaforolimus	DMLHEU7	Sarcoma	2A60-2C35	Phase 3	[19]
AZD2014	DMOEARH	Solid tumour/cancer	2A00-2F9Z	Phase 2	[20]
MM-141	DM2RJ4D	Pancreatic cancer	2C10	Phase 2	[2]
PQR309	DMMCYZ8	Squamous head and neck cell carcinom	2D60.0	Phase 2	[17]
Salirasib	DMRSU4X	Lung cancer	2C25.0	Phase 2	[17]

Drug(s) Metabolized By Cytochrome P450 2C8 (CYP2C8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[21]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[22]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[22]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[23]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[24]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[25]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[26]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[22]
Mycophenolate mofetil	DMPQAGE	Hepatosplenic T-cell lymphoma		Approved	[27]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[28]

Drug(s) Metabolized By UDP-glucuronosyltransferase 1A9 (UGT1A9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[29]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[30]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[31]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[32]
Mycophenolate mofetil	DMPQAGE	Hepatosplenic T-cell lymphoma		Approved	[33]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[32]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[32]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[34]
Nateglinide	DMLK2QH	Diabetic complication	5A2Y	Approved	[32]
Haloperidol	DM96SE0	Delirium		Approved	[32]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Hedgehog signaling pathway (HS pathway)	TT4LXBC	NOUNIPROTAC	Inhibitor	[1]
Serine/threonine-protein kinase mTOR (mTOR)	TTCJG29	MTOR_HUMAN	Inhibitor	[3]
Smoothened homolog (SMO)	TT8J1S3	SMO_HUMAN	Modulator	[4]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4) Main DME	DE4LYSA	CP3A4_HUMAN	Substrate	[]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Substrate	[5]
UDP-glucuronosyltransferase 1A9 (UGT1A9)	DE85D2P	UD19_HUMAN	Substrate	[5]

References

• [1] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [5] Metabolism, excretion and pharmacokinetics of [14C]glasdegib (PF-04449913) in healthy volunteers following oral administration. Xenobiotica. 2017 Dec;47(12):1064-1076.
• [6] Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
• [7] Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells. Br J Cancer. 2014 Sep 9;111(6):1168-79.
• [8] Clinical pipeline report, company report or official report of Exelixis (2011).
• [9] Discovery of NVP-LEQ506, a second-generation inhibitor of smoothened. ChemMedChem. 2013 Aug;8(8):1261-5.
• [10] TAK-441, a novel investigational smoothened antagonist, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling. Int J Cancer. 2013 Oct 15;133(8):1955-66.
• [11] Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.
• [12] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [13] Development of taladegib as a sonic hedgehog signaling pathway inhibitor. Arch Pharm Res. 2017 Dec;40(12):1390-1393.
• [14] Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
• [15] Advances in kinase targeting: current clinical use and clinical trials. Trends Pharmacol Sci. 2014 Nov;35(11):604-20.
• [16] Mammalian target of rapamycin, its mode of action and clinical response in metastatic clear cell carcinoma. Gan To Kagaku Ryoho. 2009 Jul;36(7):1076-9.
• [17] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
• [18] Natural products to drugs: natural product-derived compounds in clinical trials. Nat Prod Rep. 2008 Jun;25(3):475-516.
• [19] A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
• [20] Dramatic suppression of colorectal cancer cell growth by the dual mTORC1 and mTORC2 inhibitor AZD-2014. Biochem Biophys Res Commun. 2014 Jan 10;443(2):406-12.
• [21] Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
• [22] Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
• [23] Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
• [24] Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
• [25] Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
• [26] Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
• [27] PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
• [28] Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
• [29] Polymorphic expression of UGT1A9 is associated with variable acetaminophen glucuronidation in neonates: a population pharmacokinetic and pharmacogenetic study. Clin Pharmacokinet. 2018 Oct;57(10):1325-1336.
• [30] Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos. 2005 Jul;33(7):1027-35.
• [31] Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. Invest New Drugs. 2011 Dec;29(6):1511-4.
• [32] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [33] The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet. 2011 Jan;50(1):1-24.
• [34] The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene. J Biol Chem. 2003 Apr 18;278(16):13975-83.